EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma

Kyeongjin Seo iD, Kihwan Hwang iD, Kyung Mi Nam, Min Ju Kim iD, Yoon-Kyu Song, Chae-Yong Kim iD

Pharmaceutics · 21.04.2024 · 16 (4) · 566

DOI: 10.3390/pharmaceutics16040566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 21.04.2024. Verfasst von Kyeongjin Seo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam-si 13620, Republic of Korea. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University Bundang Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-operative chemotherapy is still required for the treatment of glioblastoma (GBM), for which nanocarrier-based drug delivery has been identified as one of the most effective methods. However, the blood-brain barrier (BBB) and non-specific delivery to non-tumor tissues can significantly limit drug accumulation in tumor tissues and cause damage to nearby normal tissues. This study describes a targeted cancer therapy approach that uses AS1411 aptamer-conjugated nanospheres (100–300 nm in size) loaded with doxorubicin (Dox) to selectively identify tumor cells overexpressing nucleolin (NCL) proteins. The study demonstrates that the active target model, which employs aptamer-mediated drug delivery, is more effective than non-specific enhanced permeability and maintenance (EPR)-mediated delivery and passive drug delivery in improving drug penetration and maintenance in tumor cells. Additionally, the study reveals the potential for anti-cancer effects through 3D spheroidal and in vivo GBM xenograft models. The DNA-protein hybrid nanospheres utilized in this study offer numerous benefits, such as efficient synthesis, structural stability, high drug loading, dye labeling, biocompatibility, and biodegradability. When combined with nanospheres, the 1411 aptamer has been shown to be an effective drug delivery carrier allowing for the precise targeting of tumors. This combination has the potential to produce anti-tumor effects in the active targeted therapy of GBM.

Schlagwörter

Stichwörter der Autor:innen

AS1411DNA nanostructuresglioblastomanucleolintargeted drug delivery

Autor:innen und Institutionen

  • Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam-si 13620, Republic of Korea.
  • Department of Health Science and Technology, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Republic of Korea.
  • Department of Neurosurgery, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
  • Astrogen Inc., 440, Hyeoksin-daero, Dong-gu, Daegu 41072, Republic of Korea.
  • Department of Applied Bioengineering, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 08826, Republic of Korea.
  • Advanced Institutes of Convergence Technology, Suwon-si 16229, Republic of Korea.

ORCID-Profile: Kyeongjin Seo, Kihwan Hwang, Min Ju Kim, Chae-Yong Kim

Förderung

  • Seoul National University Bundang Hospital

Zitieren

APA

Seo, K., Hwang, K., Nam, K. M., Kim, M. J., Song, Y. K., & Kim, C. Y. (2024). Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma. Pharmaceutics, 16(4), 566. https://doi.org/10.3390/pharmaceutics16040566

Vancouver

Seo K, Hwang K, Nam KM, Kim MJ, Song YK, Kim CY. Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma. Pharmaceutics. 2024;16(4):566. doi:10.3390/pharmaceutics16040566

BibTeX
@article{Seo2024,
  author = {Seo, Kyeongjin and Hwang, Kihwan and Nam, Kyung Mi and Kim, Min Ju and Song, Yoon-Kyu and Kim, Chae-Yong},
  title = {Nucleolin-Targeting AS1411 Aptamer-Conjugated Nanospheres for Targeted Treatment of Glioblastoma},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {4},
  pages = {566},
  doi = {10.3390/pharmaceutics16040566}
}
Kostenlos starten →